Featured Conference Posters
Clinical trials of new and emerging therapies potentially offer the patient a more effective treatment. Much is happening in basic, translational and clinical research for IBD. Our clinicians interact closely with immunologists, microbiologists, geneticists, pathologists and other scientists at the University of Chicago who are working in the field of digestive diseases. Current studies are looking at the many genes associated with IBD and the role of intestinal microflora in contributing to the disorder. Whatever the area of research, we all have the same goals: to develop better and more specific treatments for IBD and ultimately to prevent and cure the disease.
Endoscopic and Histologic Response and Remission Rates in Ulcerative Colitis Patients Treated with Tofacitinib: Real-World Data From a Tertiary Center
In this treatment resistant cohort of UC patients, tofacitinib induced both endoscopic and histologic remission, often with the combined endpoint of histo-endoscopic mucosal healing.
Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis
In this cohort of patients with a preoperative diagnosis of UC, we found that deep inflammation of the resected colon is a specific predictor for fistula formation in the J pouch.
Decrease in Severity of Psychiatric Comorbidities in the IBD Population During the COVID-19 Pandemic
This study found a decrease in median anxiety and depression severity in patients with IBD after COVID-19 was declared a national emergency, and these findings were unrelated to IBD activity.
Trends in Physical Activity and Sleep Quality in IBD Patients Measured with Wearable Biosensors During the COVID-19 Pandemic
The biosensor data showed no significant changes in physical activity or sleep metrics in patients with IBD after the Illinois stay-at-home order was issued in March 2020.